Innovation in Action: OBI Pharma Sharpens Focus on ADC Products, Platforms, and Out-Licensing
Integrating Product and Platform Capabilities to Drive Global Collaboration

OBI Pharma Showcases Next-Generation ADC Development at 2025 World ADC Asia Summit

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

OBI-902 TROP2 ADC has been granted by the TFDA to proceed to Phase I/II human clinical trial

Announcement of 1st Sustainable Development Committee Members

Announcement of 6th Remuneration and Nomination Committee Members

2024 Annual Report

Learn how we created value in 2024 and worked to pursue our purpose of enabling a healthier world.

Governance

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations